

●► Alfigma*(CHMP, Positive Opinion)*

CHMP issues positive opinion for Alfigma's filgotinib to treat axSpA in patients with an inadequate response to conventional therapy

●► Novo Nordisk*(CHMP, Positive Opinion)*

Novo Nordisk gets positive CHMP opinion for SOGROYA, administered once weekly, for children with ISS and persistent growth disturbances

●► AstraZeneca*(CHMP, Positive Opinion)*

CHMP recommends positive opinion to AstraZeneca's ENHERTU as a monotherapy for the adjuvant treatment of adults with resected HER2-positive breast cancer

●► Roche*(CHMP, Positive Opinion)*

Roche gains a positive CHMP opinion for its OCREVUS IV infusion to treat patients aged 10 years and older with RMS



●► **Merck** *(CHMP, Positive Opinion)*

CHMP adopts positive opinion for Merck's KEYTRUDA in combination with PADCEV as a neoadjuvant treatment for adults with resectable MIBC

●► **Novo Nordisk** *(CHMP, Positive Opinion)*

Novo Nordisk receives positive CHMP recommendation for FREHEMGO to treat HA, with or without inhibitors, in adults and children

●► **AstraZeneca** *(FDA, Priority Review)*

FDA accepts AstraZeneca's BLA, efzimfotase alfa for priority review to treat patients aged ≥ 2 years with HPP

●► **Kestrel Therapeutics** *(FDA, Fast Track)*

FDA grants Fast Track designation to Kestrel Therapeutics' KST-6051 to treat advanced or metastatic solid tumors harboring KRAS mutations



●► **Revolution Medicines**

(FDA, Breakthrough Therapy)

Revolution Medicines obtains FDA Breakthrough Therapy designation for RASONQUE in combination with GnP for the treatment of patients with treatment-naïve metastatic PDAC

●► **Armata Pharmaceuticals**

(FDA, Breakthrough Therapy)

FDA gives Breakthrough Therapy designation to Armata Pharmaceuticals' AP-SA02 as an adjunct treatment for complicated bacteremia caused by MSSA or MRSA

●► **Sobi**

(Collaboration)

Sobi collaborates with Innate Pharma to initiate TELLOMAK-3 study in CTCL, with a payment of USD 75M

●► **Sanofi**

(Collaboration)

Sanofi collaborates with Cheplapharm to transfer 20 mature medicines and three manufacturing sites worldwide in exchange for a 26.4% equity stake



●► mAbxience*(Collaboration)*

mAbxience and Sandoz collaborate to license, develop, manufacture and commercialize emicizumab biosimilar for hemophilia A

●► Genentech*(Phase 3, Results)*

Genentech's Ph3 CELESTIMO study evaluating LUNSUMIO in combination with lenalidomide vs. RITUXAN plus lenalidomide for relapsed or refractory FL demonstrates improvement in PFS with no new safety signals

●► Definium Therapeutics*(Phase 3, Results)*

Ph3 Panorama study of Definium Therapeutics evaluating DT120 ODT in adults with GAD demonstrates improvements from baseline compared to placebo with -9.8 HAM-A score on 100 µg

